atherosclerosis

The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.

The firm is seeking funding to commercialize a malondialdehyde-acetaldehyde-adduct biomarker ELISA that it believes can help broaden access to cardiac tests.

The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.